[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100586708":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":18,"centralContacts":22,"locations":31,"responsibleParty":49,"collaborators":10,"id":51,"slug":52,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":53,"sex":59,"minAge":60,"maxAge":61,"enrollmentInfo":62,"targetDuration":10,"studyType":65,"phases":10,"briefSummary":66,"conditions":67,"keywords":71,"overallStatus":81,"whyStopped":10,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":91},{"fullName":5,"class":6},"Bezmialem Vakif University","OTHER",[8,12,15],{"label":9,"type":10,"description":11,"interventionNames":10},"Group 1: Anti-TNF treatment",null,"Psoriatic arthritis patients with outcome assessment at 24 months following the initiation of Anti-TNF biological treatment.",{"label":13,"type":10,"description":14,"interventionNames":10},"Group 2: Anti-IL17 treatment","Psoriatic arthritis patients with outcome assessment at 24 months following the initiation of Anti-IL-17 biological treatment.",{"label":16,"type":10,"description":17,"interventionNames":10},"MTX Control Group","This cohort comprises psoriatic arthritis (PsA) patients with outcome assessment at 24 months following the initiation of methotrexate (MTX) monotherapy. They will serve as the control group to compare the effects on liver health with those treated using biologic agents. No other specific interventions beyond standard MTX therapy are administered to this group.",[19],{"name":20,"affiliation":5,"role":21},"Mehmet Serkan Kılıçoğlu, MD","PRINCIPAL_INVESTIGATOR",[23,27],{"name":20,"role":24,"phone":25,"phoneExt":10,"email":26},"CONTACT","+905309734511","dr.serkan.kilicoglu@gmail.com",{"name":28,"role":24,"phone":29,"phoneExt":10,"email":30},"Safa El Mardi Alaoui, MD","+905350770520","elmardi.safa@gmail.com",[32],{"facility":5,"status":10,"city":33,"state":34,"zip":35,"country":36,"countryCode":10,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"Istanbul","Fatih","34093","Turkey (Türkiye)",{"type":38,"coordinates":39},"Point",[40,41],28.94966,41.01384,{"lat":41,"lon":40},[44,45,46,47],{"name":20,"role":24,"phone":25,"phoneExt":10,"email":26},{"name":28,"role":24,"phone":29,"phoneExt":10,"email":30},{"name":20,"role":21,"phone":10,"phoneExt":10,"email":10},{"name":28,"role":48,"phone":10,"phoneExt":10,"email":10},"SUB_INVESTIGATOR",{"type":50,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100586708","comparison-of-liver-health-in-psoriatic-arthritis-patients-using-anti-tnf-or-anti-il17-treatments-100586708",false,"NCT06918886","Comparison of Liver Health in Psoriatic Arthritis Patients Using Anti-TNF or Anti-IL17 Treatments","Evaluation of Liver Fibrosis and Hepatic Steatosis Using FIB-4 Score and Ultrasonography in Psoriatic Arthritis Patients Treated With TNF or IL-17 Inhibitors: A Retrospective Controlled Study","FIB-4 PsA","Inclusion Criteria:\n\n* Age 18 to 65 years\n* Diagnosed with psoriatic arthritis (PsA) according to standard classification criteria\n* Receiving biologic therapy (anti-TNF or anti-IL-17) or MTX monotherapy for ≥2 years\n* Able to provide historical data (medical records) on liver ultrasound and laboratory parameters\n\nExclusion Criteria:\n\n* History of any other chronic liver disease (e.g., viral hepatitis, autoimmune hepatitis)\n* Significant alcohol consumption (\\>20 g\u002Fday women, \\>30 g\u002Fday men)\n* Concomitant use of other hepatotoxic drugs apart from MTX\n* Unwillingness or inability to comply with study assessments","ALL","18 Years","65 Years",{"count":63,"type":64},90,"ESTIMATED","OBSERVATIONAL","Psoriatic arthritis (PsA) is an inflammatory joint disease that can also affect the liver. Some medications used to treat PsA, such as biological agents (TNF-alpha inhibitors and IL-17 inhibitors), may influence liver health over the long term. This retrospective study aims to evaluate the presence and progression of liver fibrosis (scarring) and hepatic steatosis (fatty liver) in PsA patients treated with TNF-alpha inhibitors or IL-17 inhibitors.\n\nThe study includes PsA patients who have used biological medications continuously for at least 2 years. Patients' liver health will be assessed using non-invasive tests such as liver ultrasonography and validated biochemical scoring systems (FIB-4, APRI). The findings will be compared with PsA patients treated only with methotrexate (MTX), a commonly used medication known to affect liver health.\n\nThis study will help understand whether biological therapies (TNF or IL-17 inhibitors) have a positive or negative impact on liver health compared to traditional treatments (MTX) in patients with psoriatic arthritis.",[68,69,70],"Psoriatic Arthritis (PsA)","Liver Fibrosis","Liver Diseases",[72,69,73,74,75,76,77,78,79,80],"Psoriatic Arthritis","FIB-4 Score","Anti-TNF Therapy","Anti-IL17 Therapy","Biological Therapy","Liver Health","Retrospective Study","Hepatic Safety","Chronic Inflammatory Arthritis","NOT_YET_RECRUITING","2025-04-07",{"date":84,"type":85},"2025-04-09","ACTUAL",{"date":87,"type":64},"2025-04-10",{"date":89,"type":64},"2025-05-01",{"name":5,"class":6},1]